It is a phase 1/2 study aiming to determine the safety of dual-specificity CD38 and BCMA CAR-T cells, as well as the feasibility of producing enough cells to treat patients with r/r MM. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.